Multiple Myeloma

Biology, Standard Therapy, and Transplant Therapy

Morie Gertz, Irene Ghobrial, Jean Luc-Harousseau

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of novel agents has led to a significant increase in survival. Combinations of novel agents are expected to provide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autologous and allogeneic stem cell transplantation remains an integral part of therapy further improving the outcomes following induction with novel agents.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number1 SUPPL.
DOIs
StatePublished - Jan 1 2009

Fingerprint

Plasma Cells
Multiple Myeloma
Transplants
Stem Cell Transplantation
Apoptosis
Recurrence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • genetics
  • multiple myeloma
  • Stem Cell Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Multiple Myeloma : Biology, Standard Therapy, and Transplant Therapy. / Gertz, Morie; Ghobrial, Irene; Luc-Harousseau, Jean.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 1 SUPPL., 01.01.2009, p. 46-52.

Research output: Contribution to journalArticle

Gertz, Morie ; Ghobrial, Irene ; Luc-Harousseau, Jean. / Multiple Myeloma : Biology, Standard Therapy, and Transplant Therapy. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 1 SUPPL. pp. 46-52.
@article{1168f63f96ca4cbc95ee23b13fef3e2b,
title = "Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy",
abstract = "The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of novel agents has led to a significant increase in survival. Combinations of novel agents are expected to provide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autologous and allogeneic stem cell transplantation remains an integral part of therapy further improving the outcomes following induction with novel agents.",
keywords = "Chemotherapy, genetics, multiple myeloma, Stem Cell Transplantation",
author = "Morie Gertz and Irene Ghobrial and Jean Luc-Harousseau",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2008.10.006",
language = "English (US)",
volume = "15",
pages = "46--52",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Multiple Myeloma

T2 - Biology, Standard Therapy, and Transplant Therapy

AU - Gertz, Morie

AU - Ghobrial, Irene

AU - Luc-Harousseau, Jean

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of novel agents has led to a significant increase in survival. Combinations of novel agents are expected to provide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autologous and allogeneic stem cell transplantation remains an integral part of therapy further improving the outcomes following induction with novel agents.

AB - The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of novel agents has led to a significant increase in survival. Combinations of novel agents are expected to provide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autologous and allogeneic stem cell transplantation remains an integral part of therapy further improving the outcomes following induction with novel agents.

KW - Chemotherapy

KW - genetics

KW - multiple myeloma

KW - Stem Cell Transplantation

UR - http://www.scopus.com/inward/record.url?scp=64749098712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749098712&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.10.006

DO - 10.1016/j.bbmt.2008.10.006

M3 - Article

VL - 15

SP - 46

EP - 52

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 SUPPL.

ER -